The CANTOS trial, which was a randomized control trial of canakinumab, a monoclonal antibody targeting IL-1β, demonstrated that inhibition of IL-1β decreased the rate of recurrent cardiovascular events and that blocking IL-1β could decrease lung cancer incidence and mortality (47, 48). The gene discussed is IL1B; the disease is lung carcinoma.